Catalyst Pharmaceuticals (CPRX) Long-Term Investments (2018 - 2026)

Catalyst Pharmaceuticals has reported Long-Term Investments for 6 years, with the latest figure at $27.3 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments rose 12.71% year-over-year to $27.3 million; the trailing twelve-month figure through Mar 2026 stood at $27.3 million (up 12.71% YoY), and the FY2025 full-year result was $22.5 million, up 4.51% from the prior year.
• Long-Term Investments for Q1 2026 stood at $27.3 million, up from $22.5 million in the prior quarter.
• The five-year high for Long-Term Investments was $27.3 million in Q1 2026, with the low at $12.9 million in Q3 2023.
• Historically, Long-Term Investments has averaged $19.0 million across 4 years, with a median of $19.2 million in 2025.
• The largest YoY upside for Long-Term Investments was 62.47% in 2025 against a maximum downside of 4.51% in 2025.
• Catalyst Pharmaceuticals' Long-Term Investments stood at $16.5 million in 2023, then jumped by 30.78% to $21.6 million in 2024, then increased by 4.51% to $22.5 million in 2025, then grew by 21.08% to $27.3 million in 2026.
• The last three Long-Term Investments figures came in at $27.3 million (Q1 2026), $22.5 million (Q4 2025), and $19.2 million (Q3 2025), per Business Quant data.